ArticleJournal of gynecologic oncology2025
Fertility-sparing treatment outcomes using immune checkpoint inhibitors in endometrial cancer patients with Lynch syndrome.
Article in Journal of gynecologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Review
- Clinical utility of diagnosing Lynch syndrome in gynecologic oncology: a joint statement from four Japanese academic societies.International journal of clinical oncology · 2026Review
- Clinical Benefit of Pembrolizumab in Lynch Syndrome-Associated Advanced Ovarian Cancer With GermlineClinical case reports · 2026Article
- Review
- Oncological and reproductive outcomes following fertility-preserving treatment in mismatch repair-deficient endometrial cancer or atypical endometrial hyperplasia.BMC women's health · 2026Article
- Global trends in fertility-preserving treatment for endometrial cancer: a bibliometric analysis, 2005-2024.Discover oncology · 2026Article
- Updates and evolving care paradigms for pre-menopausal patients with endometrial cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026Review
- Case Report: Immunotherapy-containing fertility-sparing treatment integrated with preimplantation genetic testing resulting in live birth in Lynch syndrome-associated endometrial cancer.Frontiers in oncology · 2026Article
- Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges.Frontiers in oncology · 2026Review
- Clinical and fertility outcomes in lynch syndrome patients with endometrial carcinoma or endometrial Intraepthelial neoplasia treated with fertility sparing management.Gynecologic oncology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo evaluate the efficacy of immune checkpoint inhibitors (ICIs) for fertility-sparing treatment in Lynch syndrome-associated endometrial cancer (LS-EC).
methodsFour LS-EC cases received programmed cell death protein 1 (PD-1) inhibitors for fertility preservation at the Obstetrics and Gynecology Hospital of Fudan University from 2017 to 2023. The clinical data and long-term outcomes were retrospectively reviewed.
resultsCase 1, carrying germline
conclusionICIs might be an effective choice for LS-EC patients desiring fertility preservation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.